2025
Cerebrospinal fluid and brain positron emission tomography measures of synaptic vesicle glycoprotein 2A: Biomarkers of synaptic density in Alzheimer's disease
Mecca A, Ashton N, Chen M, O'Dell R, Toyonaga T, Zhao W, Young J, Salardini E, Bates K, Ra J, Goodcase S, Silva‐Rudberg J, Nabulsi N, Brinkmalm A, Kvartsberg H, Schöll M, Nilsson J, Arnsten A, Huang Y, Hansson O, Zetterberg H, Carson R, Blennow K, van Dyck C. Cerebrospinal fluid and brain positron emission tomography measures of synaptic vesicle glycoprotein 2A: Biomarkers of synaptic density in Alzheimer's disease. Alzheimer's & Dementia 2025, 21: e70344. PMID: 40491249, PMCID: PMC12149441, DOI: 10.1002/alz.70344.Peer-Reviewed Original ResearchConceptsSynaptic vesicle glycoprotein 2APositron emission tomographyAlzheimer's diseaseSynaptic densityEnzyme-linked immunosorbent assayC]UCB-J positron emission tomographyPositron emission tomography measurementsEmission tomographyAxonal proteinsCN participantsImmunosorbent assaySymptomatic Alzheimer's diseaseAD groupProteinAssayParticipantsSV2AAlzheimerCerebrospinal fluidBrainInvestigate associationsCerebrospinal fluid assaysSV2A positron emission tomography
2024
Synaptic density patterns in early Alzheimer’s disease assessed by independent component analysis
Fang X, Raval N, O’Dell R, Naganawa M, Mecca A, Chen M, van Dyck C, Carson R. Synaptic density patterns in early Alzheimer’s disease assessed by independent component analysis. Brain Communications 2024, 6: fcae107. PMID: 38601916, PMCID: PMC11004947, DOI: 10.1093/braincomms/fcae107.Peer-Reviewed Original ResearchMedial temporal brain regionsAlzheimer's diseaseTemporal brain regionsCognitive deficitsBrain regionsCognitive impairmentPostmortem studiesBinds to SV2ASynaptic densityReduction of synaptic densityIndependent component analysisSynaptic lossAlzheimerDeficitsImpairmentBrainNeocortexComponent analysisPrimary pathologySV2ASynaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse loss
2015
Chapter 28 Mas and Neuroprotection in Stroke
Bennion D, Regenhardt R, Mecca A, Sumners C. Chapter 28 Mas and Neuroprotection in Stroke. 2015, 201-205. DOI: 10.1016/b978-0-12-801364-9.00028-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply